Company intelligence / Profile preview

Pluromed

Woburn, Massachusetts, United Statessmgconferences.com ↗

Ownership: Private
Development stage: Commercial

Overview

Pluromed developed FDA-approved and CE-marked hydrogel devices such as LeGoo® for temporary vascular occlusion, with clinical use in over a thousand procedures. BackStop® was commercialized globally via Boston Scientific. The company’s pipeline included advanced-stage interventional oncology products. The company was acquired by Sanofi to expand its biosurgery portfolio. No new independent clinical results post-acquisition.

Therapeutic areas: OncologyCardiovascularNephrology
Modalities: DeviceHydrogel-based drug delivery therapy (for LeGoo and related products)Polymer-drug conjugate therapy (for proprietary polymer technology)
Industry: Therapeutic Medical Devices

Partnerships

Boston Scientific (distribution agreement for BackStop)

Beyond the preview

Go deeper on Pluromed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pluromed.

Explore the full profile